Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.894 |
High Similarity |
NPD4965 |
Approved |
0.894 |
High Similarity |
NPD4966 |
Approved |
0.894 |
High Similarity |
NPD4967 |
Phase 2 |
0.8742 |
High Similarity |
NPD37 |
Approved |
0.8701 |
High Similarity |
NPD6234 |
Discontinued |
0.8581 |
High Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.8438 |
Intermediate Similarity |
NPD7228 |
Approved |
0.8239 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.8121 |
Intermediate Similarity |
NPD7240 |
Approved |
0.8025 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7895 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7895 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7879 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7872 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7824 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7821 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7808 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7798 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7765 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.7718 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7697 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7667 |
Intermediate Similarity |
NPD7680 |
Approved |
0.7662 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.766 |
Intermediate Similarity |
NPD1357 |
Approved |
0.764 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7613 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7582 |
Intermediate Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.7582 |
Intermediate Similarity |
NPD6004 |
Phase 3 |
0.7582 |
Intermediate Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.7582 |
Intermediate Similarity |
NPD6005 |
Phase 3 |
0.7582 |
Intermediate Similarity |
NPD6002 |
Phase 3 |
0.758 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7569 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7562 |
Intermediate Similarity |
NPD7028 |
Phase 2 |
0.7546 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7544 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7542 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7482 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7471 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.747 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.7467 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7438 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7434 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7417 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7417 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7412 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7412 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7403 |
Intermediate Similarity |
NPD2438 |
Suspended |
0.7401 |
Intermediate Similarity |
NPD7296 |
Approved |
0.74 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.74 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7372 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7368 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7362 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7361 |
Intermediate Similarity |
NPD17 |
Approved |
0.7347 |
Intermediate Similarity |
NPD1283 |
Approved |
0.7338 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7333 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7321 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7317 |
Intermediate Similarity |
NPD5563 |
Clinical (unspecified phase) |
0.7315 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7308 |
Intermediate Similarity |
NPD5958 |
Discontinued |
0.7305 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7303 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7303 |
Intermediate Similarity |
NPD2979 |
Phase 3 |
0.7294 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7289 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7285 |
Intermediate Similarity |
NPD3764 |
Approved |
0.7283 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7279 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7273 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.726 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7248 |
Intermediate Similarity |
NPD5647 |
Approved |
0.7241 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7237 |
Intermediate Similarity |
NPD4062 |
Phase 3 |
0.7225 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7222 |
Intermediate Similarity |
NPD1894 |
Discontinued |
0.7219 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7219 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7212 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7212 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.72 |
Intermediate Similarity |
NPD8313 |
Approved |
0.72 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7195 |
Intermediate Similarity |
NPD6386 |
Approved |
0.7195 |
Intermediate Similarity |
NPD6385 |
Approved |
0.7191 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7184 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7181 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7179 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7178 |
Intermediate Similarity |
NPD7458 |
Discontinued |
0.7172 |
Intermediate Similarity |
NPD5585 |
Approved |
0.7153 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7152 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7143 |
Intermediate Similarity |
NPD1281 |
Approved |
0.7143 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7143 |
Intermediate Similarity |
NPD1535 |
Discovery |
0.7135 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7135 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7135 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7134 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7134 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7126 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7125 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7118 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7117 |
Intermediate Similarity |
NPD3687 |
Approved |
0.7117 |
Intermediate Similarity |
NPD3686 |
Approved |
0.7108 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7108 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7108 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7104 |
Intermediate Similarity |
NPD4420 |
Approved |
0.7102 |
Intermediate Similarity |
NPD7281 |
Phase 3 |
0.7102 |
Intermediate Similarity |
NPD7280 |
Phase 3 |
0.7099 |
Intermediate Similarity |
NPD6273 |
Approved |
0.7095 |
Intermediate Similarity |
NPD1481 |
Phase 2 |
0.7091 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7089 |
Intermediate Similarity |
NPD4534 |
Discontinued |
0.7086 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7078 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7078 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7078 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7076 |
Intermediate Similarity |
NPD5242 |
Approved |
0.7075 |
Intermediate Similarity |
NPD3847 |
Discontinued |
0.707 |
Intermediate Similarity |
NPD6032 |
Approved |
0.7066 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7059 |
Intermediate Similarity |
NPD3268 |
Approved |
0.7052 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7051 |
Intermediate Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.7044 |
Intermediate Similarity |
NPD4237 |
Approved |
0.7044 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7044 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7037 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7037 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7037 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7032 |
Intermediate Similarity |
NPD1933 |
Approved |
0.703 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7025 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.702 |
Intermediate Similarity |
NPD6007 |
Clinical (unspecified phase) |
0.7013 |
Intermediate Similarity |
NPD6663 |
Approved |
0.7006 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.7 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD8166 |
Discontinued |
0.6989 |
Remote Similarity |
NPD7039 |
Approved |
0.6989 |
Remote Similarity |
NPD7038 |
Approved |
0.6981 |
Remote Similarity |
NPD970 |
Clinical (unspecified phase) |
0.6975 |
Remote Similarity |
NPD4357 |
Discontinued |
0.6975 |
Remote Similarity |
NPD1511 |
Approved |
0.6974 |
Remote Similarity |
NPD9494 |
Approved |
0.6972 |
Remote Similarity |
NPD228 |
Approved |
0.697 |
Remote Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.6964 |
Remote Similarity |
NPD5353 |
Approved |
0.6962 |
Remote Similarity |
NPD2531 |
Phase 2 |
0.6957 |
Remote Similarity |
NPD5084 |
Clinical (unspecified phase) |
0.6954 |
Remote Similarity |
NPD6362 |
Approved |
0.6952 |
Remote Similarity |
NPD5006 |
Approved |
0.6952 |
Remote Similarity |
NPD5005 |
Approved |
0.6948 |
Remote Similarity |
NPD1699 |
Clinical (unspecified phase) |
0.6939 |
Remote Similarity |
NPD1651 |
Approved |
0.6933 |
Remote Similarity |
NPD4359 |
Approved |
0.6933 |
Remote Similarity |
NPD3688 |
Clinical (unspecified phase) |
0.6933 |
Remote Similarity |
NPD2983 |
Phase 2 |
0.6933 |
Remote Similarity |
NPD3146 |
Approved |
0.6933 |
Remote Similarity |
NPD2982 |
Phase 2 |
0.6928 |
Remote Similarity |
NPD4908 |
Phase 1 |
0.6928 |
Remote Similarity |
NPD2614 |
Approved |
0.6923 |
Remote Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.6919 |
Remote Similarity |
NPD7315 |
Approved |
0.6918 |
Remote Similarity |
NPD2343 |
Clinical (unspecified phase) |
0.6914 |
Remote Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.6913 |
Remote Similarity |
NPD1610 |
Phase 2 |
0.6905 |
Remote Similarity |
NPD7819 |
Suspended |
0.6905 |
Remote Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.6903 |
Remote Similarity |
NPD8032 |
Phase 2 |
0.6899 |
Remote Similarity |
NPD5588 |
Approved |
0.6894 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6892 |
Remote Similarity |
NPD5125 |
Phase 3 |
0.6892 |
Remote Similarity |
NPD5126 |
Approved |
0.6892 |
Remote Similarity |
NPD1778 |
Approved |
0.689 |
Remote Similarity |
NPD1512 |
Approved |
0.6889 |
Remote Similarity |
NPD8434 |
Phase 2 |
0.6882 |
Remote Similarity |
NPD7075 |
Discontinued |
0.6882 |
Remote Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.6871 |
Remote Similarity |
NPD6799 |
Approved |
0.6867 |
Remote Similarity |
NPD2981 |
Phase 2 |
0.6863 |
Remote Similarity |
NPD3018 |
Phase 2 |
0.6863 |
Remote Similarity |
NPD5736 |
Approved |
0.6855 |
Remote Similarity |
NPD4476 |
Approved |
0.6855 |
Remote Similarity |
NPD4477 |
Approved |
0.6848 |
Remote Similarity |
NPD5403 |
Approved |
0.6845 |
Remote Similarity |
NPD6801 |
Discontinued |
0.6842 |
Remote Similarity |
NPD919 |
Approved |
0.6839 |
Remote Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.6832 |
Remote Similarity |
NPD3060 |
Approved |
0.6832 |
Remote Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.6832 |
Remote Similarity |
NPD2976 |
Clinical (unspecified phase) |
0.6831 |
Remote Similarity |
NPD3021 |
Approved |
0.6831 |
Remote Similarity |
NPD3022 |
Approved |
0.6826
|
Remote Similarity |
NPD6599 |
Discontinued |